This Form 144 is consistent with a pre-arranged 10b5-1 plan and does not signal a change in insider conviction. Monitor the company's upcoming earnings and pipeline catalysts for fundamental developments; the insider sale itself is not a trading signal.
Price Chart
Executive Summary
Sanjiv Patel, a director and officer of Relay Therapeutics, filed a Form 144 notice of intent to sell 96,401 shares of common stock, with an estimated aggregate market value of approximately $1.81 million based on the filing date. The shares were acquired via restricted stock units vesting on 02/10/2025, and the notice references prior 10b5-1 plan sales in August and September 2026, suggesting this sale is part of a pre-arranged trading plan. Given the insider's role and the modest size relative to the company's market cap, this filing is a routine liquidity event with no material directional signal.
Key Facts
- Sanjiv Patel (Director and Officer) filed Form 144 to sell 96,401 shares of common stock.
- Estimated aggregate market value of the proposed sale is $1,806,554.74 based on the filing date.
- Shares were acquired via restricted stock units vesting on 02/10/2025.
- The filing references prior 10b5-1 plan sales on 08/17/2026 (48,199 shares) and 09/08/2026 (48,199 shares).
- The sale is proposed to occur on or after 10/07/2026 through Morgan Stanley Smith Barney LLC.
Financial Impact
Proposed sale of 96,401 shares valued at ~$1.81M, representing a small fraction of the company's market cap.
Risk Factors
- Insider selling, even under a 10b5-1 plan, can be perceived negatively by the market if volume is large relative to average daily trading volume.
Investment Themes
Documents Analyzed
This report is based on 3 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 144 Filing (Primary) | 0001950047-26-010107 |
| Document: 0001950047-26-010107-index.html | 0001950047-26-010107 |
| Document: 0001950047-26-010107.txt | 0001950047-26-010107 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 7, 2026 21d ago | 144 | $17.41 | awaiting T+60 | awaiting T+60 | $19.82 (+13.84%) |
Oct 6, 2026 22d ago | 144 | $17.95 | awaiting T+60 | awaiting T+60 | $19.82 (+10.42%) |
Sep 9, 2026 7w ago | Insider Cluster | $18.89 | awaiting T+60 | awaiting T+60 | $19.82 (+4.92%) |
Aug 28, 2026 8w ago | Insider Cluster | $18.77 | awaiting T+60 | awaiting T+60 | $19.82 (−5.59%) |
Aug 18, 2026 10w ago | Insider Cluster | $20.74 | awaiting T+60 | awaiting T+60 | $19.82 (+4.44%) |
Jul 8, 2026 16w ago | Insider Cluster | $20.75 $18.96 | ▼ −8.63% | ▼ −11.01% | $19.82 (−4.48%) |
Jun 22, 2026 18w ago | 144 | $17.44 $18.84 | ▲ +8.03% | ▲ +4.78% | $19.82 (+13.65%) |
Jun 12, 2026 19w ago | Institutional Cluster | $14.81 $19.11 | ▲ +29.03% | ▲ +25.77% | $19.82 (+33.83%) |
May 21, 2026 22w ago | 8-K | $13.53 $20.61 | ▼ −52.33% | ▼ −49.14% | $19.82 (−46.49%) |
May 20, 2026 23w ago | Press Release | $13.66 $20.67 | ▼ −51.32% | ▼ −47.02% | $19.82 (−45.10%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers